Only patient 2 is monotherapy. Patient 1 is in the clinical trial and therefore must be treated with chemotherapy and leronlimab. With patients 3 and 4 one is a trial patient and will follow protocol and the other is IND. Whether the IND patient is a combo patient or mono will be up to the patient and the doctor treating her.